2016
,
The significance of tumor cMET and HGF expression status for prediction of the treatment response of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) patients harboring EGFR activating mutation